CN117357460A - 一种针对中重度敏感肌的舒敏特护精华及其制备方法 - Google Patents
一种针对中重度敏感肌的舒敏特护精华及其制备方法 Download PDFInfo
- Publication number
- CN117357460A CN117357460A CN202311568667.7A CN202311568667A CN117357460A CN 117357460 A CN117357460 A CN 117357460A CN 202311568667 A CN202311568667 A CN 202311568667A CN 117357460 A CN117357460 A CN 117357460A
- Authority
- CN
- China
- Prior art keywords
- skin
- comfort
- ceramide
- test
- special care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 13
- 230000008439 repair process Effects 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 230000003020 moisturizing effect Effects 0.000 claims description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 8
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 8
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 8
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 241000590031 Alteromonas Species 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- VKIJBOMCWLTQBD-UHFFFAOYSA-N benzoic acid N-(2-hydroxyphenyl)propanamide Chemical compound C(C1=CC=CC=C1)(=O)O.C(CC)(=O)NC1=C(C=CC=C1)O VKIJBOMCWLTQBD-UHFFFAOYSA-N 0.000 claims description 4
- 229960003237 betaine Drugs 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- 229940101267 panthenol Drugs 0.000 claims description 4
- 235000020957 pantothenol Nutrition 0.000 claims description 4
- 239000011619 pantothenol Substances 0.000 claims description 4
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229940083542 sodium Drugs 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 241001071795 Gentiana Species 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 claims description 3
- KZTJQXAANJHSCE-OIDHKYIRSA-N N-octodecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC KZTJQXAANJHSCE-OIDHKYIRSA-N 0.000 claims description 3
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- GCDXVKZXCQGDHC-BLCQCPAESA-N [30-oxo-30-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC GCDXVKZXCQGDHC-BLCQCPAESA-N 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229940086668 ceramide eop Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 2
- 229940060184 oil ingredients Drugs 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 230000008591 skin barrier function Effects 0.000 abstract description 15
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 5
- 229940091886 4-tert-butylcyclohexanol Drugs 0.000 abstract description 3
- 229940116815 crocus sativus flower extract Drugs 0.000 abstract description 3
- 206010042674 Swelling Diseases 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 62
- 210000003491 skin Anatomy 0.000 description 58
- 239000000047 product Substances 0.000 description 26
- 241000252212 Danio rerio Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 10
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001506371 Kadsura Species 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 235000015655 Crocus sativus Nutrition 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 241001135871 Gentiana scabra Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 244000223604 Mauritia flexuosa Species 0.000 description 2
- 235000010080 Mauritia flexuosa Nutrition 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000010831 paired-sample T-test Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 240000004429 Tephrosia purpurea Species 0.000 description 1
- 235000017517 Tephrosia purpurea Nutrition 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940114077 acrylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical compound C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000000876 binomial test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- -1 ethyl caproic acid Chemical compound 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆用的配制品技术领域,具体涉及一种针对中重度敏感肌的舒敏特护精华及其制备方法。其针对中重度敏感肌的舒敏特护精华包含有成分4‑叔丁基环己醇、南五味子提取物、灰毛豆籽提取物、番红花花提取物。本发明从多通道方向减少受损肌肤的红肿、瘙痒、炎症等损伤,加强皮肤屏障功能,改善肌肤状态。
Description
技术领域
本发明属于化妆用的配制品技术领域,具体涉及一种针对中重度敏感肌的舒敏特护精华及其制备方法。
背景技术
皮肤作为人体抵御外界侵害的第一道保护层,具有保护、吸收与排泄、调节体温和感受外界刺激等作用,即皮肤具有特殊的屏障作用。狭义上,皮肤屏障主要指物理屏障,其由皮脂膜、角质层角蛋白、脂质、“三明治”结构、砖墙结构等共同构成,能有效抵御外界有害物对肌肤造成损伤,同时具有保湿及调节抗炎作用。
随着社会发展生活节奏加快,人们生活压力增大,同时,肌肤也备受压力。在日晒、熬夜、不良化学品使用、空气污染、长期带口罩、医美等因素的影响下,皮肤屏障受损,使皮肤出现红肿、发热、瘙痒、疼痛等现象。
目前为了应对此类问题,通常会加入抗敏剂来抑制炎症因子对皮肤造成损伤,然而这其只是减少了炎症症状的发生,并没有对肌肤屏障损伤进行修复;有害物质仍然可以进入表皮层从而对肌肤造成损伤。
发明内容
本发明提供了一种针对中重度敏感肌的舒敏特护精华及其制备方法,能快速舒缓肌肤、改善泛红、修护皮肤屏障、长期维稳肌肤的精华液。
一种舒敏特护组合物,以质量份计算,包含以下成分:
特别的,还包含以下成分
交替单胞菌发酵产物提取物 0.001-0.01
龙胆根提取物 0.02-1
羟苯基丙酰胺苯甲酸 0.005-0.5。
特别的,还包括保湿成分,所述保湿成分的添加量为2-8份;所述保湿成分包括以下的至少一种:
1,3-丙二醇、丁二醇、甜菜碱、海藻糖、甘露糖醇、甘油。
特别的,还包括修护成分,所述修护成分的添加量为0.1-8份;所述修护成分包括以下的至少一种:
角鲨烷、季戊四醇四(乙基己酸)酯、毛瑞榈果油、透明质酸、透明质酸钠、聚谷氨酸钠、泛醇、尿囊素、胶原、神经酰胺NP、神经酰胺NS/神经酰胺NG、神经酰胺AS、神经酰胺EOP、神经酰胺AP。
本发明还提供所述的舒敏特护组合物在制备在制备化妆品中的应用。
本发明提供一种针对中重度敏感肌的舒敏特护精华,包含前述的舒敏特护组合物。
特别的,针对中重度敏感肌的舒敏特护精华还包含至少一种化妆品领域可接受的辅助剂;包括但不限于:防腐剂、乳化剂、螯合剂、粘度调节剂。
本发明的有益效果:
4-叔丁基环己醇、南五味子提取物、灰毛豆籽提取物、番红花花提取物组成的组合对皮肤的舒缓效果突出。
其中4-叔丁基环己醇是有效的TRPV 1的拮抗剂,有效舒缓肌肤的不适感。
南五味子提取物通过清除自由基发挥抗氧化作用,而且对皮肤细胞的氧化应激也表现出很好的保护作用。
灰毛豆籽提取物能够分解皮肤细胞产生的皮质醇,激活一种作用于情绪的天然镇静神经肽的释放,从而快速阻止紧张和压力信号传输给皮肤,达到舒缓的效果。
番红花花提取物能有效抑制氧自由基及黄嘌呤氧化酶的活性,表现出抗氧化的生物活性,强化肌肤屏障的效果。
本发明选用多元醇、甜菜碱与海藻糖的保湿搭配,协助皮肤吸收水分,增加表层皮肤含水量。
交替单胞菌发酵产物提取物有效降低皮肤反应性,为朗格汉斯细胞提供保护,有助于维持最佳的皮肤免疫防御系统,降低敏感肌肤的不适感。
龙胆(GENTIANA SCABRA)根提取物对荧光素酶的有很好的活化效果,说明对特异性皮炎和过敏有作用,可抑制刺激,起到抗炎的作用;其主要成分龙胆苦苷对热和化学刺激引起的疼痛反应有明显的缓和作用。
羟苯基丙酰胺苯甲酸抑制NK1受体的活性并阻断引发痒感的组胺释放,减少肌肤红肿和痒感。
健康的肌肤是光滑、柔软有弹性的,皮肤的柔韧不仅与含水量有关,还与皮肤含脂质量有关,水油平衡更是健康肌肤的衡量标准之一。本发明科学搭配水油修护体系,复合PGA、神经酰胺、胶原等皮肤重要组成分,修护肌肤屏障,维持水油平衡,改善肌肤状态。
聚谷氨酸钠PGA与神经酰胺作为皮肤中的组成成分,促进皮肤内天然保湿成分的蓄积,显著提升肌肤内天然保湿因子(NMF)的含量,增强皮肤屏障功能。
胶原蛋白是细胞外基质的主要组成成分,是体内含量最多、分布最广的蛋白质之一,促进真皮细胞成长,修复受损老化的组织。小分子透明质酸与泛醇渗入角质层,提高皮肤水合作用,减少皮肤的水分流失,改善皮肤粗糙度,激活成纤维细胞增殖,加速上皮细胞再生,修护受损肌肤同时增强皮肤屏障作用。
大分子量的透明质酸可以吸收自身重量500倍的水分,迅速稀释皮肤最外面的皮脂膜形成均匀透气的水膜,防止水分流水。
油脂选用角鲨烷、季戊四醇四(乙基己酸)酯与毛瑞榈(MAURITIA FLEXUOSA)果油科学搭配,提供清爽柔嫩肤感,润滑皮肤表面,填充皮肤表面空间,代替皮肤损失的脂质,形成保护膜,修护肌肤屏障,改善皮肤外观。本发明科学搭配的水油修护体系,有效提高皮肤水含量,补充损失的脂质,加强皮肤屏障,维持皮肤水油平衡的健康状态。
本发明从多通道方向减少受损肌肤的红肿、瘙痒、炎症等损伤,加强皮肤屏障功能,改善肌肤状态。
附图说明
图1为使用产品前后角质层水分含量参数对比分析图。
图2为使用产品前后皮肤水分流失率参数对比分析图。
图3为使用产品前后皮肤泛红参数对比分析图。
图4为使用产品前后紧绷感评分参数对比分析图。
图5为使用产品前后粗糙感评分参数对比分析图。
图6为使用产品前后干燥感评分参数对比分析图。
图7为使用产品前后肌肤敏感度评分参数对比分析图。
图8为其中部分有效例子的泛红改善情况。
具体实施方式
为了更好地理解本发明,下面结合具体实施例对本发明作进一步的描述,其中实施例中使用的术语是为了描述特定的具体实施方案,不构成对本发明保护范围的限制。
实施例中,所使用的实验方法如无特殊说明,均为常规方法,所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本发明所使用原料来源:
湖州浦瑞生物医药技术有限公司:透明质酸、透明质酸钠、聚谷氨酸钠、氢化卵磷脂、聚丙烯酸钠、神经酰胺NP、神经酰胺NS/神经酰胺NG、神经酰胺AS、神经酰胺EOP、神经酰胺AP。
广东云星生物技术有限公司:精氨酸、麦芽糊精、胶原、甘露糖醇、海藻糖、辛酰羟肟酸。
妆莱(广州)生物研究有限公司:对羟基苯乙酮、EDTA二钠、尿囊素、甜菜碱、1,3-丙二醇、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物。
上海麦克林生化科技股份有限公司:甘油、角鲨烷、季戊四醇四(乙基己酸)酯、4-叔丁基环己醇、1,2-戊二醇、丁二醇、1,2-己二醇、泛醇、羟苯基丙酰胺苯甲酸、抗坏血酸棕榈酸酯。
广州优楷生物科技有限公司:交替单胞菌发酵产物提取物(西班牙)。
广州市金宝来生物科技有限公司:毛瑞榈(MAURITIA FLEXUOSA)果油。
陕西昊辰生物科技有限公司:南五味子(SCHISANDRA SPHENANTHERA)提取物、龙胆(GENTIANA SCABRA)根提取物、灰毛豆(TEPHROSIA PURPUREA)籽提取物、番红花(CROCUSSATIVUS)花提取物。
针对中重度敏感肌的舒敏特护精华的制备
按以下步骤制备对应的样品
(1)按表1称取各组分;
(2)将A相原料加入乳化锅中,搅拌加热至80-85℃,适当均质,溶解完全,保温。
(2)将B相原料加入油相锅中,搅拌升温至80-85℃,混合分散均匀,备用。
(3)80-85℃下,将B相原料加入乳化锅中,搅拌均质乳化完全,保温(15-20)分钟。
(4)乳化锅中降温至60℃,加入预先溶解完全的C(C相原料预先混合加热60-65℃搅拌溶解完全)、D相原料(D相原料预先混合搅拌溶解完全),搅拌均匀。
(5)乳化锅降温至42-45℃,依次加入预先分散溶解完全的E相(E相原料预先混合搅拌溶解完全)、F相(F相原料预先混合搅拌溶解完全)和G相原料,搅拌均匀。适当均质,搅拌均匀。
(6)乳化锅温度降至38℃时,取样送检,检验合格后,停止搅拌关闭冷却水;乳化锅抽内压,用200目滤网过滤卸料。
表1
表1(续)
表1中“-”表示不存在,当实施例中对应的相无任何物质时,则跳过对应的相关步骤。
人体皮肤斑贴测试
将获得的12组样品参照《2022化妆品安全技术规范》中的人体皮肤斑贴实验。
分别于30min(待压痕消失后)、24h和48h按标准观察皮肤反应,并记录观察结果;没有出现任何不良反应。
对MMP-1表达的抑制测试
研究证明,紫外线辐射的表皮角质形成细胞释放出细胞因子,可间接促进真皮成纤维细胞的MMP-1表达。而MMP-1可降解多型的胶原明胶及蛋白多糖,是使皮肤出现皱缩、无弹性等老化症状的原因之一;故通过测试前述制备的样品对MMP-1的抑制率来评估这些样品的皮肤屏障修复效果。
将成纤维细胞接种到12孔细胞培养板中,每个孔含有0.75×105个细胞,并且在无血清培养基中饥饿培养24小时。用PBS冲洗经饥饿培养的细胞,并且用紫外光处理(40mJ)。然后,在48小时内,向细胞中加入测试样品2次。用试剂盒(BIOTRAK,RPN2610)测量培养基中分离的MMP-1。通过计算MMP-1的表达抑制率来评估皮肤屏障修复功效的强弱,结果如表2所示;计算公式如下:
抑制率=(A-B)/A*100%
A:未添加测试样品,但经紫外照射后MMP-1的表达量
B:添加测试样品经紫外照射后MMP-1的表达量
表2对MMP-1表达的抑制率
根据序号2与序号3-10、序号11的对比可知,本发明添加的保湿成分和修护成分对MMP-1有轻微的作用;而起到最主要作用的为4-叔丁基环己醇、南五味子提取物、灰毛豆籽提取物、番红花花提取物组成的舒敏组合;次要影响因素为交替单胞菌发酵产物提取物、龙胆根提取物、羟苯基丙酰胺苯甲酸组成的褪红舒缓组合。
舒缓抗敏功效测试
利用斑马鱼模型对样品进行舒缓抗敏功效测试。
1、十二烷基硫酸钠诱导的斑马鱼体表炎症试验
组别设置:空白对照组(斑马鱼胚胎培养液);模型对照组(斑马鱼胚胎培养液+60μg/mL十二烷基硫酸钠);实验组(斑马鱼胚胎培养液+60μg/mL十二烷基硫酸钠+样品)。
测试方法:采用CZ59的转基因品系斑马鱼,期间剔除死亡胚胎,收集胚胎,放置于玻璃容器中培养72hpf,期间剔除死亡胚胎。将胚胎10枚一组转移至6孔板中饲养,按组别设置进行暴露,培养24h。培养完成后,置于荧光显微镜下观察中性粒细胞形成的情况,并拍照,统计斑马鱼体表的中性粒细胞迁移数目。
2、冰乙酸诱导的斑马鱼体表刺痛试验
组别设置:空白对照组(斑马鱼胚胎培养液);模型对照组(斑马鱼胚胎培养液+0.009%冰乙酸);实验组(斑马鱼胚胎培养液+0.009%冰乙酸+样品)。
采用AB品系斑马鱼,期间剔除死亡胚胎,收集胚胎,放置于玻璃容器中培养72hpf,期间剔除死亡胚胎。将胚胎30枚一组转移至6孔板中饲养,按组别设置进行暴露,培养24h后,提取其总RNA,进行逆转录后qPCR法检测其trpv1mRNA的相对表达水平。
3、测试结果
在十二烷基硫酸钠诱导的斑马鱼体表炎症试验中,实验组能够显著减少斑马鱼体表的中性粒细胞数量,有效缓解十二烷基硫酸钠造成的斑马鱼体表炎症;在冰乙酸诱导的斑马鱼体表刺痛模型,实验组能够显著减少斑马鱼trpv1 mRNA的相对表达水平,有效缓解冰乙酸诱导的斑马鱼体表刺痛;结果如表3所示。。
表3
组别 | 中性粒细胞迁移数 | trpv1mRNA相对水平表达 |
空白对照组 | 7.0 | 1.0 |
模型对照组 | 38.0 | 4.0 |
序号1 | 17.0 | 3.5 |
序号2 | 15.5 | 3.0 |
序号3 | 13.5 | 3.0 |
序号4 | 14.0 | 3.0 |
序号5 | 13.5 | 3.0 |
序号6 | 13.0 | 3.0 |
序号7 | 13.0 | 3.0 |
序号8 | 13.5 | 3.0 |
序号9 | 12.5 | 2.5 |
序号10 | 13.0 | 3.0 |
序号11 | 30.5 | 4.0 |
序号12 | 26.5 | 4.0 |
人体试验
1.测试目的
通过不少于30名中国女性志愿者连续使用一款样品4周,采用无创仪器测试、临床评估并结合志愿者问卷调研方式,综合评价对精华的保湿、舒缓和修护功效。
2.伦理声明
根据赫尔辛基宣言,志愿者的选择遵循人体测试的医学和伦理学标准,所有志愿者的测试都必须出于志愿者本人自愿,并在测试前签署知情同意书。志愿者在签署知情同意书之前,测试人员需要告知志愿者本次测试的目的,可能的利益,潜在的风险和问题以及相关的权力和义务。
3.试验依据
(1)QB/T4256—2011《化妆品保湿功效评价指南》
(2)TZHCA003-2018化妆品影响经表皮水分流失测试方法
(3)T/ZHCA005-2019化妆品影响皮肤弹性测试方法
(4)TGDCDC019-2021化妆品抗皱功效测试方法
(5)本实验室方法
4.试验样品信息
4.1试验样品信息
样品名称:前述序号9所制得样品。
数量与规格:45瓶
4.2试验样品使用说明
使用频率:早晚各一次
使用部位:全脸
使用方法:每日早晚清洁肌肤后,取适量精华液,避开眼周,直接涂抹于面部肌肤,按摩至吸收即可。
5.测试环境
温度:21.0℃±1.0℃;湿度:50%±10%RH
6.志愿者
所有的志愿者都依照当地法规、规程接受口头和纸质的知情同意。知情同意解释了研究的性质、目的和参与研究的潜在风险,并强调参与测试的自愿性,志愿者可以随时出于任何理由退出研究。所有的志愿者都可以就研究进行提问,在签署前给与充分的时间考虑。所有的知情同意签署必须是在研究开始前进行。
6.1入选标准
①25~45岁,健康女性;
②中重度敏感:经乳酸刺痛评分≥4分;
③面部有泛红问题;
④测试部位无皮肤病、色素沉积、瘀痕或可影响皮肤的全身疾病;
⑤可以良好的配合使用样品、理解并填写项目问卷并配合工作人员。
6.2排除标准
①具有过敏体质、过敏性皮肤炎等,有皮肤病或疾病史(严重雀斑、异位性皮肤病、银屑病、湿疹严重痤疮等),临床评判认为不适合参加该项目的人员;
②实验部位有大面积胎记、抓痕、白斑、色素痣、疤痕疙瘩等其它影响试验的皮肤表征;
③妊娠、哺乳期、更年期;
④其它影响本次实验的要求;
⑤近2月内参加过其他临床试验者;
⑥同行或其他试验负责人或视感评估师判断不适合本试验对象的人。
6.3限制事项
①实验当天实验部位不使用任何护肤品(包括发放样品),也不要化妆。实验时,携带所有发放的样品和使用记录;
②实验期间,除指定样品替换为实验样品外,您不能使用其它任何在使用的样品。不能服用任何治疗皮肤病的药物,不进行外科美容手术或去美容院护理。避免阳光下活动和长时间外出旅行;
③其它限制事项(其它要求,按项目需求)。
6.4志愿者情况
共有32名志愿者完成测试,年龄在27~45岁之间,平均年龄37.59±5.41岁。
志愿者人数和信息如下:
筛选人数:46
入组人数:32
退出人数:0
完成人数:32
分析人数:32
平均年龄±标准差:37.59±5.41
最小年龄:27
最大年龄:45
7.测试方法
7.1测试流程
基础值(使用前):
(1)志愿者首次到访当天不可使用护肤品和化妆,对志愿者进行试验说明,并签署知情同意书。
(2)使用温和洁面产品清洁面部后,进入恒温恒湿间内静坐30分钟。
(3)按照试验要求进行筛选。
(4)按照测试内容进行仪器测试和临床评估(基础值)。
(5)仪器测试结束后,对志愿者介绍产品使用方法,发放产品。
(6)首次到访结束。
第2周(连续使用产品2周后):
(7)志愿者回访当天不可使用护肤品和化妆,到访后,使用温和洁面产品清洁面部,进入恒
温恒湿间内静坐30分钟。
(8)检查志愿者的使用记录,并对产品进行称重。
(9)按照测试内容进行仪器测试和临床评估(第2周),并完成自评问卷。
(10)第2周回访结束。
第4周(连续使用产品4周后):
(11)志愿者回访当天不可使用护肤品和化妆,到访后,使用温和洁面产品清洁面部,进入恒温恒湿间内静坐30分钟。
(12)检查志愿者的使用记录,并对产品进行称重。
(13)按照测试内容进行仪器测试和临床评估(第4周),并完成自评问卷。
(14)测试流程结束。
具体测试内容及日程如下表4
表4
表4中“○”表示实施,“-”表示不实施。
7.2测试内容及设备
7.2.1仪器测试
(1)角质层水分含量:使用Corneometer(Courage&Khazaka,德国)测试一侧面颊部位,测试3次取平均值。
参数解释:参数值越大,皮肤角质层水分含量越高。
(2)经表皮水分流失率:使用Tewameter(Courage&Khazaka,德国)测试一侧面颊部位40s,取后20s取平均值。
参数解释:参数值越小,皮肤经表皮水分流失率越低,皮肤屏障越好。
(3)皮肤红度a*值:使用VISIA-CR(Canfield,美国)拍摄受试者面部区域,并使用IPP软件分析面部泛红a*值。
参数解释:参数值越小,皮肤红度a*值越低,面部泛红程度越轻。
7.2.2主观评估
(4)乳酸刺痛评分:在受试者鼻唇沟部位进行乳酸刺痛试验,计算刺痛评分。
参数解释:评分越小,说明肌肤敏感度越低。
(5)视感评估(紧绷感、粗糙度、干燥感):医生采用十分制评分标准为:0分表示不明显;1-3分表示有些明显;4-6分表示明显;7-9分表示非常明显;10分表示极明显。
(6)安全性评估:医生评估面部皮肤反应分级,统计不良反应发生数。
采用《化妆品安全技术规范2015版》中“人体试用试验皮肤反应分级标准”。
(7)自评问卷:受试者对测试品的感官喜好度及功效认同度进行评分,并统计满意项百分比(4分+5分)。
8数据统计分析方法
应用EXCEL软件对各测试时点测量值进行描述性统计,包括均值、标准误差。
仪器测试&图像分析结果:应用SPSS软件进行统计分析,先对各参数的数据变化值进行正态分布检验,Sig.(双侧)>0.05,则呈正态分布,进行配对样本t检验;若Sig.(双侧)<0.05,则呈非正态分布,进行Wilcoxon符号秩检验,显著性差异水平α取0.05。
等级评分结果:应用SPSS软件,进行Wilcoxon符号秩检验,显著性差异水平α取0.05。
自评结果:统计自评分数在4分和5分的数量和百分比。
9.测试结果
9.1仪器测试结果
9.1.1角质层水分含量测试结果
使用第2周,皮肤水分含量相比基础值提升了19.56%,具有显著性差异(p<0.001)。
使用第4周,皮肤水分含量相比基础值提升了35.05%,具有显著性差异(p<0.001)。
具体测试结果见表5,图1。
表5
注:1.改变率(%)=(2周/4周测试值均值-基础值均值)/基础值均值*100%,下同。
2.p值统计方法:a表示配对样本t检验,b表示Wilcoxon符号秩检验,下同。
3.显著性标记解释:p≥0.05,“n.s.”表示无统计学差异;p<0.05,表示有显著性差异;其中,“*”表示0.01≤p<0.05;“**”表示
0.001≤p<0.01;“***”表示p<0.001。下同。
9.1.2皮肤水分流失率参数测试结果
使用第2周,皮肤水分流失率相比基础值减少了12.90%,具有显著性差异(p<0.001)。
使用第4周,皮肤水分流失率相比基础值减少了27.97%,具有显著性差异(p<0.001)。
具体测试结果见表6,图2。
表6
9.1.3皮肤泛红度a*值测试结果
使用第2周,皮肤泛红相比基础值改善了5.25%,具有显著性差异(p=0.024)。
使用第4周,皮肤泛红相比基础值改善了6.64%,具有显著性差异(p<0.001)。
具体测试结果见表7,图3。
表7
9.2主观评估结果
9.2.1临床评估测试结果
使用第2周:
紧绷感评分相比基础值改善了10.34%,具有显著性差异(p=0.005)。
粗糙感评分相比基础值改善了16.67%,具有显著性差异(p<0.001)。
干燥感评分相比基础值改善了12.40%,具有显著性差异(p=0.005)。
使用第4周:
紧绷感评分相比基础值改善了14.66%,具有显著性差异(p<0.001)。
粗糙感评分相比基础值改善了17.46%,具有显著性差异(p<0.001)。
干燥感评分相比基础值改善了16.53%,具有显著性差异(p=0.001)。
肌肤敏感度评分相比基础值改善了37.88%,具有显著性差异(p<0.001)。
如表8所示、图4、5、6、7所示。
表8
9.2.2受试者满意度调查结果
志愿者在使用测试产品后进行评分,选项Q1-Q14:1分代表非常不满意或非常不认同,2分代表不满意或不认同,3分代表不确定,4分代表满意或认同,5分代表非常满意或非常认同。以问卷结果中所有有益项的累计百分比作为满意度(有益项为4分和5分)。统计结果见下表9。
表9
注:1.p值:采用二项式检验,有益项(4+5)检验比例为0.5。
9.3产品使用情况
由下表10可知,产品使用符合试验要求。
表10
上述详细说明是针对本发明其中之一可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明所为的等效实施或变更,均应包含于本发明技术方案的范围内。
Claims (7)
1.一种舒敏特护组合物,其特征在于,以质量份计算,包含以下成分:
2.根据权利要求1所述的舒敏特护组合物,其特征在于,还包含以下成分
交替单胞菌发酵产物提取物 0.001-0.01
龙胆根提取物 0.02-1
羟苯基丙酰胺苯甲酸 0.005-0.5。
3.根据权利要求1所述的舒敏特护组合物,其特征在于,还包括保湿成分,所述保湿成分的添加量为2-8份;所述保湿成分包括以下的至少一种:
1,3-丙二醇、丁二醇、甜菜碱、海藻糖、甘露糖醇、甘油。
4.根据权利要求1所述的舒敏特护组合物,其特征在于,还包括修护成分,所述修护成分的添加量为0.1-8份;所述修护成分包括以下的至少一种:
角鲨烷、季戊四醇四(乙基己酸)酯、毛瑞榈果油、透明质酸、透明质酸钠、聚谷氨酸钠、泛醇、尿囊素、胶原、神经酰胺NP、神经酰胺NS/神经酰胺NG、神经酰胺AS、神经酰胺EOP、神经酰胺AP。
5.权利要求1-4任一所述的舒敏特护组合物在制备在制备化妆品中的应用。
6.一种针对中重度敏感肌的舒敏特护精华,其特征在于,包含权利要求1-4任一所述的舒敏特护组合物。
7.根据权利要求6所述的针对中重度敏感肌的舒敏特护精华,其特征在于,还包含至少一种化妆品领域可接受的辅助剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311568667.7A CN117357460B (zh) | 2023-11-23 | 2023-11-23 | 一种针对中重度敏感肌的舒敏特护精华及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311568667.7A CN117357460B (zh) | 2023-11-23 | 2023-11-23 | 一种针对中重度敏感肌的舒敏特护精华及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117357460A true CN117357460A (zh) | 2024-01-09 |
CN117357460B CN117357460B (zh) | 2024-04-12 |
Family
ID=89393065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311568667.7A Active CN117357460B (zh) | 2023-11-23 | 2023-11-23 | 一种针对中重度敏感肌的舒敏特护精华及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117357460B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108498448A (zh) * | 2018-04-07 | 2018-09-07 | 广州市索柔生物科技有限公司 | 一种提高皮肤耐受性的组合物及其制备方法 |
CN110237014A (zh) * | 2019-07-04 | 2019-09-17 | 上海绿瑞生物科技有限公司 | 一种具有舒缓作用的水油双相组合物及其制备方法 |
CN116036000A (zh) * | 2023-03-07 | 2023-05-02 | 浙江犀望生物科技有限公司 | 一种抗敏精华液及其制备方法 |
CN116712342A (zh) * | 2023-06-09 | 2023-09-08 | 诺德溯源(广州)生物科技有限公司 | 一种舒缓皮肤红、热、痛的高渗透性包裹体及其制备方法和应用 |
-
2023
- 2023-11-23 CN CN202311568667.7A patent/CN117357460B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108498448A (zh) * | 2018-04-07 | 2018-09-07 | 广州市索柔生物科技有限公司 | 一种提高皮肤耐受性的组合物及其制备方法 |
CN110237014A (zh) * | 2019-07-04 | 2019-09-17 | 上海绿瑞生物科技有限公司 | 一种具有舒缓作用的水油双相组合物及其制备方法 |
CN116036000A (zh) * | 2023-03-07 | 2023-05-02 | 浙江犀望生物科技有限公司 | 一种抗敏精华液及其制备方法 |
CN116712342A (zh) * | 2023-06-09 | 2023-09-08 | 诺德溯源(广州)生物科技有限公司 | 一种舒缓皮肤红、热、痛的高渗透性包裹体及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117357460B (zh) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102406576B (zh) | 一种含有青刺果油的功效性护肤品及制备方法 | |
CN115137665B (zh) | 一种具有长效保湿及舒缓功效的组合物及其应用 | |
CN103330658B (zh) | 具有修复受损皮脂膜、舒缓皮肤压力的护肤组合物 | |
WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
CN114376949B (zh) | 一种精华面膜及其制备方法和应用 | |
CN110302091A (zh) | 一种含烟酰胺腺嘌呤二核苷酸的抗皮肤衰老组合物及其制备方法和用途 | |
CN113662900A (zh) | 一种具有舒缓修复及提亮皮肤功效的组合物及制备方法和应用 | |
CN112107533A (zh) | 一种具有控油嫩肤并收细毛孔功效的组合物及其制备方法和应用 | |
Sadowski et al. | Safety and efficacy of a novel antiaging skin care regimen containing neutraceuticals and growth factors on the facial skin of women: a 12-week open-label study | |
CN113749974A (zh) | 一种清痘修护面膜及其制备方法 | |
CN108721154A (zh) | 一种用于皮肤保湿和屏障修复的护肤品及其制备方法 | |
CN117357460B (zh) | 一种针对中重度敏感肌的舒敏特护精华及其制备方法 | |
CN116617106A (zh) | 一种原人参三醇皂苷舒敏修护组合物及其制备方法和应用 | |
CN113940909B (zh) | 一种调节昼夜节律的组合物及其应用 | |
CN114903810B (zh) | 一种含肽抗皱组合物及其应用 | |
CN115737451A (zh) | 一种α-凝胶组合物、化妆品及其制备方法 | |
CN108354891A (zh) | 一种舒缓乳霜及其制备方法 | |
CN114272188A (zh) | 一种抗皱精华露及其制备方法 | |
CN112933024A (zh) | 一种含工业大麻提取物的修护面霜及其制备方法 | |
CN111166688A (zh) | 青蒿烯作为保湿抗皱、抗衰老成分在化妆品中的应用 | |
CN111096914A (zh) | 一种大麻叶净颜平衡面膜及其制作方法 | |
CN115337216B (zh) | 一种具有舒缓功效的护肤品组合及其制备 | |
CN116725935B (zh) | 一种具有美白抗敏抗皱的精华组合物及其制备方法和应用 | |
CN115844796B (zh) | 具有祛痘、焕肤、缓释功效的油包水组合物及应用 | |
CN115969759B (zh) | 光保护植物提取组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |